不同剂量丙种球蛋白治疗川崎病的疗效及对患儿冠脉病变的影响

目的：分析不同剂量丙种球蛋白（IVIG）在川崎病（KD）临床治疗中的应用价值。方法：回顾性分析2012年1月～2014年1月我院儿科收治确诊为川崎病48例患儿的临床资料，根据IVIG治疗剂量进行分组，给予IVIG 1g/kg剂量治疗24例为观察组，给予IVIG 2g/kg剂量治疗24例为对照组，观察比较两组治疗效果及随访患儿冠脉病变（CAL）影响。结果：观察组平均黏膜充血时间少于对照组，差异具有统计学意义（P<0.05），而两组患儿热退、手足肿胀消退、淋巴结肿大消退时间比较均无显著差异（P>0.05）；观察组CAL发生率虽然略高于对照组，但差异无统计学意义（P>0.05）。结论：1g/kg剂量IVIG治疗川崎病不仅能达到常规2g/kg剂量的治疗及降低患儿CAL发生率的效果，而且相对经济、安全，值得临床推广。

The therapeutic effect o n different dosage of intravenous immune globulin in the treatment of Kawasaki disease and its influence on coronary artery lesion

Objective:To analysis and research the therapeutic value of different dosage of intravenous immune globulin (IVIG) to treat Kawasaki disease (KD). Methods:According to received different IVIG treatment dosage , the treated 48 cases of Kawasaki disease patients in January 2012-January 2014 were chosed, randomly divided into two groups, each of 24 cases. Grouping measures:Observation group were treated with 1g/kg of IVIG in intravenous injection while control group were treated with 2g/kg of IVIG in intravenous injection. Comparing the the differences of therapeutic effect and its influence on coronary artery lesion (CAL) of two groups after the treatment. Result:The pyretolysis time, regression time of hand and foot swelling, and regression time of cervical lymph node of two groups showed no significant difference (P>0.05), while regression time of mucosa hyperemia of observation group was less than that of control group (P<0.05);compared with control group, CAL incidence of observation group was slightly higher, but the difference was not statistically significant(P>0.05). Conclusion:In the treatment of Kawasaki disease , IVIG(1g/kg) is not only able to achieve same therapeutic and reducing the incidence of CAL effect compared with IVIG 2g/kg , but also comparatively economical, safe, which is worthy of promotion.